株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

2型糖尿病:パイプライン製品の分析

Type 2 Diabetes - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232774
出版日 ページ情報 英文 1298 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
2型糖尿病:パイプライン製品の分析 Type 2 Diabetes - Pipeline Review, H2 2016
出版日: 2016年11月09日 ページ情報: 英文 1298 Pages
概要

2型糖尿病は慢性的な症状で、最もよく見られる糖尿病です。血糖値が高いのが特徴で、体がインスリンに対して抵抗したり、十分なインスリンを生成することができなくなります。

当レポートでは、2型糖尿病の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

2型糖尿病の概要

治療薬の開発

2型糖尿病:企業で開発中の治療薬

2型糖尿病:大学/機関で研究中の治療薬

2型糖尿病:パイプライン製品の概況

2型糖尿病:企業で開発中の製品

2型糖尿病:大学/機関で研究中の製品

2型糖尿病の治療薬開発に従事している企業

2型糖尿病:治療薬の評価

薬剤プロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8585IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H2 2016, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 18, 25, 71, 54, 6, 252, 85 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 66 and 20 molecules, respectively.Type 2 Diabetes.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Type 2 Diabetes Overview
  • Therapeutics Development
  • Type 2 Diabetes - Therapeutics under Development by Companies
  • Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes
  • Type 2 Diabetes - Pipeline Products Glance
  • Type 2 Diabetes - Products under Development by Companies
  • Type 2 Diabetes - Products under Investigation by Universities/Institutes
  • Type 2 Diabetes - Companies Involved in Therapeutics Development
  • Type 2 Diabetes - Therapeutics Assessment
  • Drug Profiles
  • Type 2 Diabetes - Dormant Projects
  • Type 2 Diabetes - Discontinued Products
  • Type 2 Diabetes - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type 2 Diabetes, H2 2016
  • Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Development by Companies, H2 2016 (Contd..30)
  • Products under Development by Companies, H2 2016 (Contd..31)
  • Products under Development by Companies, H2 2016 (Contd..32)
  • Products under Development by Companies, H2 2016 (Contd..33)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
  • Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by Adocia, H2 2016
  • Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by Aegis Therapeutics, LLC, H2 2016
  • Type 2 Diabetes - Pipeline by AFFiRiS AG, H2 2016
  • Type 2 Diabetes - Pipeline by Alize Pharma SAS, H2 2016
  • Type 2 Diabetes - Pipeline by AlphaMab Co., Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by Alteogen Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Ambrx, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Amgen Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by AntriaBio, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Aphios Corporation, H2 2016
  • Type 2 Diabetes - Pipeline by APT Therapeutics, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by ArisGen SA, H2 2016
  • Type 2 Diabetes - Pipeline by Artery Therapeutics, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H2 2016
  • Type 2 Diabetes - Pipeline by AstraZeneca Plc, H2 2016
  • Type 2 Diabetes - Pipeline by Aus Bio Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by Bayer AG, H2 2016
  • Type 2 Diabetes - Pipeline by Beta-Cell NV, H2 2016
  • Type 2 Diabetes - Pipeline by Betagenon AB, H2 2016
  • Type 2 Diabetes - Pipeline by Biocon Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Biodel Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Biogenomics Limited, H2 2016
  • Type 2 Diabetes - Pipeline by BioLingus AG, H2 2016
  • Type 2 Diabetes - Pipeline by BioRestorative Therapies, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by BioTherapeutics Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H2 2016
  • Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H2 2016
  • Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Caldan Therapeutics Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Cardax, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Carlina Technologies SAS, H2 2016
  • Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H2 2016
  • Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Type 2 Diabetes - Pipeline by CJ HealthCare Corp., H2 2016
  • Type 2 Diabetes - Pipeline by CohBar, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by ConjuChem, LLC, H2 2016
  • Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Corium International, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by CureDM, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Dance Biopharm Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Delpor, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Diabetica Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by DiaMedica Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Diamyd Medical AB, H2 2016
  • Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by DiscoveryBiomed, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by DNJ Pharma, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Elcelyx Therapeutics Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Eli Lilly and Company, H2 2016
  • Type 2 Diabetes - Pipeline by enGene, Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Eternygen GmbH, H2 2016
  • Type 2 Diabetes - Pipeline by Evotec AG, H2 2016
  • Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by FibroStatin SL, H2 2016
  • Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H2 2016
  • Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H2 2016
  • Type 2 Diabetes - Pipeline by Genfit SA, H2 2016
  • Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H2 2016
  • Type 2 Diabetes - Pipeline by Gero Corp, H2 2016
  • Type 2 Diabetes - Pipeline by Geropharm, H2 2016
  • Type 2 Diabetes - Pipeline by Gilead Sciences, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Glucox Biotech AB, H2 2016
  • Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Handok Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by HEC Pharm Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Type 2 Diabetes - Pipeline by HitGen LTD, H2 2016
  • Type 2 Diabetes - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Immuron Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Innopharmax Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Innovative Targeting Solutions Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Integral Molecular, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Intrexon Corporation, H2 2016
  • Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Islet Sciences, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Ixchel Pharma, LLC, H2 2016
  • Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by JHL Biotech, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Johnson & Johnson, H2 2016
  • Type 2 Diabetes - Pipeline by Kadimastem Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Type 2 Diabetes - Pipeline by Kareus Therapeutics, SA, H2 2016
  • Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Type 2 Diabetes - Pipeline by Leading BioSciences, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by LG Life Science LTD., H2 2016
  • Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by LipimetiX Development Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Lonestar Heart, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Longevity Biotech, Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Magnus Life Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H2 2016
  • Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H2 2016
  • Type 2 Diabetes - Pipeline by MedImmune LLC, H2 2016
  • Type 2 Diabetes - Pipeline by Mellitech SAS, H2 2016
  • Type 2 Diabetes - Pipeline by Merck & Co., Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Mesoblast Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Metabolic Solutions Development Company, LLC, H2 2016
  • Type 2 Diabetes - Pipeline by Metabolys SAS, H2 2016
  • Type 2 Diabetes - Pipeline by Metacrine, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by MicroBiome Therapeutics LLC, H2 2016
  • Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H2 2016
  • Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Type 2 Diabetes - Pipeline by Moderna Therapeutics Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Naia Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Neurimmune Holding AG, H2 2016
  • Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Nordic Bioscience A/S, H2 2016
  • Type 2 Diabetes - Pipeline by Novapeutics, LLC, H2 2016
  • Type 2 Diabetes - Pipeline by Novartis AG, H2 2016
  • Type 2 Diabetes - Pipeline by NovaTarg Therapeutics, Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H2 2016
  • Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H2 2016
  • Type 2 Diabetes - Pipeline by Ogeda SA, H2 2016
  • Type 2 Diabetes - Pipeline by Omeros Corporation, H2 2016
  • Type 2 Diabetes - Pipeline by OPKO Biologics Ltd, H2 2016
  • Type 2 Diabetes - Pipeline by OPKO Health, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Orbis Biosciences Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H2 2016
  • Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
  • Type 2 Diabetes - Pipeline by Peptron, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Pfizer Inc., H2 2016
  • Type 2 Diabetes - Pipeline by PharmaCyte Biotech, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by PharmaIN Corporation, H2 2016
  • Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Pila Pharma AB, H2 2016
  • Type 2 Diabetes - Pipeline by Pivot Pharmaceuticals Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Poxel SA, H2 2016
  • Type 2 Diabetes - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Type 2 Diabetes - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by ReCyte Therapeutics, Inc., H2 2016
  • Type 2 Diabetes - Pipeline by Red Glead Discovery AB, H2 2016
  • Type 2 Diabetes - Pipeline by RegenMedTX, LLC, H2 2016
  • Type 2 Diabetes - Pipeline by reMYND NV, H2 2016
  • Type 2 Diabetes - Pipeline by Renova Therapeutics Inc, H2 2016
  • Type 2 Diabetes - Pipeline by Saniona AB, H2 2016
  • Type 2 Diabetes - Pipeline by Sanofi, H2 2016
  • Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by SATT Conectus Alsace SAS, H2 2016
  • Type 2 Diabetes - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016
  • Type 2 Diabetes - Pipeline by Selvita S.A., H2 2016

List of Figures

  • Number of Products under Development for Type 2 Diabetes, H2 2016
  • Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top